VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 9, 2007) - EnWave Corporation (TSX VENUTURE:ENW)(FRANKFURT:E4U) (“EnWave” or “the Company”) is pleased to report that it has received a non-repayable contribution of CDN $300,000 from the National Research Council Canada Industrial Research Assistance Program (“NRC-IRAP”). The funds will be used to further develop EnWave’s proprietary vaccine and antibody dehydration technology, called bioREV.
